Cyclosporin-A in vitro decreases bone resorption, osteoclast formation, and the fusion of cells of the monocyte-macrophage lineage
- PMID: 1999178
- DOI: 10.1210/endo-128-3-1638
Cyclosporin-A in vitro decreases bone resorption, osteoclast formation, and the fusion of cells of the monocyte-macrophage lineage
Abstract
We studied the in vitro effect of cyclosporin-A (CyA) on bone resorption using a fetal rat long bone-resorbing assay. CyA inhibited both PTH-stimulated and unstimulated bone resorption. The inhibitory effect of CyA on basal resorption was dose dependent, and it was more pronounced during the second period (less than or equal to 0.1 microgram/ml) of culture (days 5-7) than during the first period (days 2-4). A cytotoxic effect was ruled out by the absence of decrease in [3H]thymidine incorporation into bones up to a concentration of 5 micrograms/ml CyA. Histomorphometry performed after 4 and 7 days of culture showed that CyA (1 microgram/ml) decreased the number of osteoclasts per bone section after 7 days of culture (23.5 +/- 4.0 vs. 41.7 +/- 2.9 osteoclasts/bone section; P less than 0.05), but not after 4 days (25.6 +/- 3.3 vs. 23.0 +/- 2.5). These data suggested an effect of CyA on osteoclastic differentiation rather than on the function of mature osteoclasts. We further assessed the mechanisms of the inhibitory effect of CyA on osteoclastic differentiation in order to determine 1) the level of this action (proliferation and/or fusion of osteoclast precursors), and 2) if this action is direct or indirect. Autoradiographic studies were performed on bone sections after incubation of bones with [3H]thymidine for the last 48 h of culture. CyA decreased slightly but significantly the percentage of labeled nuclei per osteoclast and the number of osteoclasts containing at least one labeled nucleus (20.2 +/- 0.7 vs. 33.2 +/- 3.5; P less than 0.02). Moreover the number of nuclei per osteoclast was decreased after 7 days in CyA-treated bones (2.4 +/- 0.05 vs. 3.0 +/- 0.1; P less than 0.02). Taken together these results demonstrate that CyA slightly decreased the proliferation of osteoclast precursors, but markedly decreased their fusion. Similar effects were observed in cultures of rat marrow macrophages. CyA (1 microgram/ml) inhibited the fusion of macrophages into multinucleated cells elicited by 1 nM 1,25-dihydroxyvitamin D3, but had only a slight effect on the proliferation of these cells, as assessed by autoradiography. CyA also inhibited the formation of multinucleated cells and the fusion index in long term cultures of human cord blood monocytes, a cellular model for osteoclastic differentiation. By contrast, CyA had no effect on the formation of myotubes by fusion of cultured mononucleated rat myoblasts.(ABSTRACT TRUNCATED AT 400 WORDS)
Similar articles
-
Colony stimulating factor-1 plays a role in osteoclast formation and function in bone resorption induced by parathyroid hormone and parathyroid hormone-related protein.J Bone Miner Res. 1996 Oct;11(10):1474-81. doi: 10.1002/jbmr.5650111014. J Bone Miner Res. 1996. PMID: 8889847
-
DNA synthesis is not necessary for osteoclastic responses to parathyroid hormone in cultured fetal rat long bones.J Clin Invest. 1983 Dec;72(6):1924-9. doi: 10.1172/JCI111156. J Clin Invest. 1983. PMID: 6643680 Free PMC article.
-
In vitro and ex vivo evidence that estrogens suppress increased bone resorption induced by ovariectomy or PTH stimulation through an effect on osteoclastogenesis.J Bone Miner Res. 1995 Oct;10(10):1523-30. doi: 10.1002/jbmr.5650101013. J Bone Miner Res. 1995. PMID: 8686508
-
Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.Dan Med Bull. 2011 May;58(5):B4277. Dan Med Bull. 2011. PMID: 21535989 Review.
-
Morphology and biochemistry of bone remodeling: possible control by vitamin D, parathyroid hormone, and other substances.Lab Invest. 1988 Oct;59(4):418-42. Lab Invest. 1988. PMID: 3050272 Review.
Cited by
-
A functional link between dynamin and the actin cytoskeleton at podosomes.J Cell Biol. 2000 Jul 24;150(2):377-89. doi: 10.1083/jcb.150.2.377. J Cell Biol. 2000. PMID: 10908579 Free PMC article.
-
Management of endocrine disease: Secondary osteoporosis: pathophysiology and management.Eur J Endocrinol. 2015 Sep;173(3):R131-51. doi: 10.1530/EJE-15-0118. Epub 2015 May 13. Eur J Endocrinol. 2015. PMID: 25971649 Free PMC article. Review.
-
International consensus recommendations on cyclosporin use in rheumatoid arthritis.Drugs. 1995;50 Suppl 1:48-56. doi: 10.2165/00003495-199500501-00008. Drugs. 1995. PMID: 8714799 Review.
-
Enhancement of Flow-Induced AP-1 Gene Expression by Cyclosporin A Requires NFAT-Independent Signaling in Bone Cells.Cell Mol Bioeng. 2014 Jun 1;7(2):254-265. doi: 10.1007/s12195-014-0321-3. Cell Mol Bioeng. 2014. PMID: 25484988 Free PMC article.
-
Effects of cyclosporin A on rat osteoblasts (ROS 17/2.8 cells) in vitro.Calcif Tissue Int. 1992 Oct;51(4):291-7. doi: 10.1007/BF00334490. Calcif Tissue Int. 1992. PMID: 1330239
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources